Young Hyuck Im

667 total citations
27 papers, 526 citations indexed

About

Young Hyuck Im is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Young Hyuck Im has authored 27 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Young Hyuck Im's work include HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Breast Cancer Treatment Studies (4 papers). Young Hyuck Im is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Breast Cancer Treatment Studies (4 papers). Young Hyuck Im collaborates with scholars based in South Korea, United States and China. Young Hyuck Im's co-authors include Won Ki Kang, Chul Won Jung, Kihyun Kım, Mark H. Lee, Keunchil Park, Yeon Hee Cho, Woo Hyun Park, Joon Oh Park, Dominic Poulin and Jin Seok Ahn and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and Journal of the American Academy of Dermatology.

In The Last Decade

Young Hyuck Im

26 papers receiving 516 citations

Peers

Countries citing papers authored by Young Hyuck Im

Since Specialization

Citations

This map shows the geographic impact of Young Hyuck Im's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Young Hyuck Im with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Young Hyuck Im more than expected).

Fields of papers citing papers by Young Hyuck Im

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Young Hyuck Im. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Young Hyuck Im. The network helps show where Young Hyuck Im may publish in the future.

Co-authorship network of co-authors of Young Hyuck Im

This figure shows the co-authorship network connecting the top 25 collaborators of Young Hyuck Im. A scholar is included among the top collaborators of Young Hyuck Im based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Young Hyuck Im. Young Hyuck Im is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study. 2022 ·Journal of Clinical Oncology ·Keun Wook Lee, Li‐Yuan Bai, Minkyu Jung, Jieer Ying, Young Hyuck Im, Do‐Youn Oh, Y. Choi, Sang Cheul Oh, Yee Chao, Huiyan Li, (unknown), Yuanyuan Bao, Yoon‐Koo Kang	12
2	A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) 2022 ·Cancer Research and Treatment ·Dae‐Won Lee, Bhumsuk Keam, Keun Seok Lee, Jin‐Hee Ahn, Joohyuk Sohn, Jin Seok Ahn, Moon Hee Lee, Jee Hyun Kim, Kyung Eun Lee, Hyo Jung Kim, Siyoung Kim, Winnie Yeo, Chan‐Young Ock, Kyung-Hun Lee, Sae‐Won Han, Sung‐Bae Kim, Young Hyuck Im, Hyun Cheol Chung, Do‐Youn Oh, Seock‐Ah Im	3
3	Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study. 2022 ·Journal of Clinical Oncology ·Keun-Seok Lee, Xiaojia Wang, Young Hyuck Im, (unknown), Huiping Li, Kun Wang, Huiyan Li, (unknown), Yuanyuan Bao, Zefei Jiang	9
4	Phase 1b/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study. 2022 ·Journal of Clinical Oncology ·Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung‐Bae Kim, Jee Hung Kim, Hee Kyung Ahn, (unknown), Kyong Hwa Park, Jee Hyun Kim, Kyoung Eun Lee, Eui‐Cheol Shin, Su‐Hyung Park, Se Hwan Yang, (unknown), (unknown), Young Chul Sung, Young Hyuck Im	2
5	Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial 2021 ·Journal of the American Academy of Dermatology ·Danbee Kang, Nayeon Kim, Young Hyuck Im, Winnie Yeo, (unknown), (unknown), Eunjoo Kim, Di Zhao, Eliseo Güallar, Jin Seok Ahn, Juhee Cho	0
6	ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. 2020 ·Journal of Clinical Oncology ·Do‐Youn Oh, Hyun Cheol Chung, Young Hyuck Im, (unknown), (unknown), (unknown), Xin Wang, Jin Wang, Huiyan Li, Yoon‐Koo Kang	6
7	Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT) 2019 ·Supportive Care in Cancer ·Danbee Kang, (unknown), Yeon Hee Park, Young Hyuck Im, Di Zhao, Eliseo Güallar, Jin Seok Ahn, Juhee Cho	5
8	Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study 2018 ·The Oncologist ·Danbee Kang, (unknown), (unknown), Young Hyuck Im, Winnie Yeo, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Hae Kwang Lee, Ji‐Hye Park, Dong‐Youn Lee, Mario E. Lacouture, Eliseo Güallar, Juhee Cho	67
9	NanoString nCounter® Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry 2017 ·Journal of Breast Cancer ·Jiyeon Hyeon, Soo Youn Cho, Min Eui Hong, So Young Kang, In‐Gu Do, Young Hyuck Im, Eun Yoon Cho	16
10	Quantitative changes in skin composition parameters due to chemotherapy in breast cancer patients: a cohort study 2015 ·Breast Cancer Research and Treatment ·Danbee Kang, Nayeon Kim, Young Hyuck Im, Yeon Hee Park, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, (unknown), Eunjoo Kim, Hae Kwang Lee, Dong‐Youn Lee, Juhee Cho	15
11	Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers 2013 ·Supportive Care in Cancer ·So Young Park, So Yeon Lim, Sang‐Won Um, Won‐Jung Koh, Man Pyo Chung, Hojoong Kim, O Jung Kwon, Hye Kyeong Park, Seok Jin Kim, Young Hyuck Im, Myung‐Ju Ahn, Gee Young Suh	20
12	55.4: Invited Paper : Development of Highly Productive In‐line Vacuum Evaporation System for OLED Lighting 2013 ·SID Symposium Digest of Technical Papers ·(unknown), Jae Ho Lee, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Young Hyuck Im, Young Jong Lee	3
13	Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01 2011 ·Breast Cancer Research and Treatment ·Seock‐Ah Im, Keun Seok Lee, Jungsil Ro, Eun Sook Lee, Youngmee Kwon, Jin‐Hee Ahn, Jin Seok Ahn, Jee Hyun Kim, Han Sung Kang, Kyung Hwan Shin, Dong‐Young Noh, In-Ae Park, Sung‐Bae Kim, Young Hyuck Im, Sung Whan Ha	9
14	Patterns of Recurrence after Breast-Conserving Treatment for Early Stage Breast Cancer by Molecular Subtype 2011 ·Journal of Breast Cancer ·Jae Myoung Noh, Doo Ho Choi, Seung Jae Huh, Won Park, Jung Hyun Yang, Seok Jin Nam, Young Hyuck Im, Jin Seok Ahn	27
15	A Comparison of Clinical Outcomes for Breast-conserving Treatment and Mastectomy for Early Breast Cancer 2008 ·Jae Myoung Noh, Won Park, Seung Jae Huh, Doo Ho Choi, Jung Hyun Yang, Seok Jin Nam, (unknown), Young Hyuck Im, Jin Seok Ahn	1
16	Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis 2003 ·Biochemical and Biophysical Research Communications ·Woo Hyun Park, Yeon Hee Cho, Chul Won Jung, Joon Oh Park, Kihyun Kım, Young Hyuck Im, Mark H. Lee, Won Ki Kang, Keunchil Park	110
17	Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis 2003 ·International Journal of Oncology ·Woo Yong Park, Chul Won Jung, Joon Park, Kihyun Kım, Won Bae Kim, Young Hyuck Im, Mark H. Lee, Won Ki Kang, Keunchil Park	40
18	Use of GCDFP-15 (BRST-2) as a Specific Immunocytochemical Marker for Diagnosis of Gastric Metastasis of Breast Carcinoma 2003 ·Cancer Research and Treatment ·Keon Woo Park, Young Hyuck Im, Jeeyun Lee, (unknown), Hyuk Lee, (unknown), Joon Oh Park, Kihyun Kım, Chul Won Jung, Young Suk Park, Won Ki Kang, (unknown), Keunchil Park	3
19	Monensin‐mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis 2002 ·British Journal of Haematology ·(unknown), Jae Goo Seol, (unknown), Won Ki Kang, Young Hyuck Im, Chul Won Jung, Byoung Kook Kim, (unknown)	51
20	Adenocarcinoma of Unknown Primary Site 2002 ·The Korean Journal of Internal Medicine ·(unknown), Won Seog Kim, Hyeran Lee, (unknown), Sung Yong Oh, Ji Hyang Kim, Kihyun Kım, Eun Mi Nam, (unknown), (unknown), Young Hyuck Im	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact